Cite
Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer.
MLA
González Martín, Antonio, et al. “Exploratory Outcome Analyses According to Stage and/or Residual Disease in the ICON7 Trial of Carboplatin and Paclitaxel with or without Bevacizumab for Newly Diagnosed Ovarian Cancer.” Gynecologic Oncology, vol. 152, no. 1, Jan. 2019, pp. 53–60. EBSCOhost, https://doi.org/10.1016/j.ygyno.2018.08.036.
APA
González Martín, A., Oza, A. M., Embleton, A. C., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Bertrand, M. A., Beale, P., Cervantes, A., Kent, E., Kaplan, R. S., Parmar, M. K. B., Scotto, N., & Perren, T. J. (2019). Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. Gynecologic Oncology, 152(1), 53–60. https://doi.org/10.1016/j.ygyno.2018.08.036
Chicago
González Martín, Antonio, Amit M. Oza, Andrew C. Embleton, Jacobus Pfisterer, Jonathan A. Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, et al. 2019. “Exploratory Outcome Analyses According to Stage and/or Residual Disease in the ICON7 Trial of Carboplatin and Paclitaxel with or without Bevacizumab for Newly Diagnosed Ovarian Cancer.” Gynecologic Oncology 152 (1): 53–60. doi:10.1016/j.ygyno.2018.08.036.